In the Treatment of Psoriatic Arthritis, Enbrel’s Future Could Be Threatened by Humira’s Early-Line Uptake

Decision Resources Unveils New Online Platform for Its Treatment Algorithms Service

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that while Amgen/Pfizer’s Enbrel was the most widely used tumor necrosis factor (TNF)-alpha inhibitor for recently treated psoriatic arthritis patients in the fourth quarter of 2010, Abbott’s Humira has superseded Enbrel as an early-line TNF-alpha inhibitor for newly diagnosed psoriatic arthritis patients. Humira’s early-line growth threatens Enbrel’s future uptake in psoriatic arthritis.

According to Treatment Algorithms in Psoriatic Arthritis, 28 percent of recently treated psoriatic arthritis patients were prescribed Enbrel, compared with 21.5 percent for Humira. Yet, among newly diagnosed psoriatic arthritis patients, Humira achieves a higher patient share than Enbrel in patients reaching the first and second line of disease-modifying antirheumatic drug (DMARD) therapy within one year of diagnosis.

“While treatment among recently treated psoriatic arthritis patients demonstrates that Enbrel maintains an edge over Humira, the findings from the analysis of newly diagnosed patients suggest that Enbrel’s future uptake in psoriatic arthritis could be threatened by Humira’s early-line use,” said Decision Resources Analyst Dancella Fernandes, Ph.D., M.B.A. “Humira’s success in early-line uptake is likely driven by its superior efficacy on skin manifestations and less frequent subcutaneous dosing.”

Enhanced Service and Platform Now Available

The analysis is part of Decision Resources’ enhanced Treatment Algorithms series, which features a new online platform. Interactive, user-friendly and with more graphical data views, the new platform enables users to easily toggle between diseases and time cohorts, which ultimately allows for more in-depth analysis on each line of therapy. Treatment Algorithms analysis is now updated quarterly to provide ongoing trending of product utilization by line of therapy and new therapy initiations. Through examination of U.S. patient-level claims data, Decision Resources’ Treatment Algorithms series provides exceptional insight into physicians’ prescribing trends and the factors that drive therapy choice, from diagnosis through multiple courses of treatment, for a specific disease.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.



CONTACT:

Decision Resources
Lisa Osgood, 781-993-2606
[email protected]
or
Decision Resources, Inc.
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.